The Impact of Sickle Cell Disease Severity on HRQOL and Economic Outcomes
April 1st 2021Disease severity was strongly associated with health-related quality of life, moderately associated with use of disability insurance, and weakly associated with household income for patients with sickle cell disease.
Read More
Lenacapavir Against HIV Demonstrates Ongoing Potential
March 16th 2021The safety and effectiveness of the long-acting agent is backed by data from trials of the drug among treatment-experienced individuals living with HIV-1 whose viral load is on the rise due to other regimens failing. Investigation continues among these patients, as well as treatment-naive patients.
Read More
Report Describes Case of Improved Outcome in MM With Personalized Medicine
March 6th 2021Researchers describe the case of an older patient who underwent myeloma drug sensitivity testing as part of an effort to identify the therapies most likely to produce a response in this difficult-to-treat population.
Read More
Marrow Lymphocyte Patterns After ASCT May Have Prognostic Value in MM
March 5th 2021Patients with multiple myeloma (MM) often relapse over time despite initially achieving a complete response without minimal residual disease following induction treatment, leaving questions about changes in the immune system and the prognosis of the disease.
Read More
Sustained MRD Negativity Predictive of Long-term Outcomes in RRMM
February 16th 2021Sustained minimal residual disease (MRD) negativity may predict long-term outcomes in relapsed/refractory multiple myeloma (RRMM), and daratumumab-based combinations show higher rates of sustained MRD negativity compared with the standard of care.
Read More
Carfilzomib Improves Renal Response Compared With Bortezomib in RRMM
February 12th 2021Carfilzomib-dexamethasone improved renal overall and complete response in patients with relapsed or refractory multiple myeloma (RRMM) compared with a regimen of bortezomib-dexamethasone in a real-world study.
Read More
Risk Factors for Increased Mortality Among Patients With MM, COVID-19 Identified
January 7th 2021Age, renal disease, and suboptimal myeloma control were among the many factors identified in a recent study as increasing the risk of death from coronavirus disease 2019 (COVID-19) for patients being treated for multiple myeloma (MM).
Read More
Dr Robert Massie: Untreated Pooled Plasma Enabled Unchecked Virus Transmission
January 5th 2021Decades ago, companies refused to heat-treat their blood products, which resulted in pooled plasma, among others, enabling many viruses to be transmitted, noted Robert K. Massie Jr, PhD, MA, of the Society for Progress.
Watch
Metabolic Biomarkers Could Predict Prognosis, Treatment Outcomes in MM
December 30th 2020New research shows metabolic biomarkers could be meaningful tools for predicting treatment outcomes in patients, based on a comparison of biomarkers, clinical characteristics, and therapeutic efficacy.
Read More